| Trial ID: | L0591 |
| Source ID: | JPRN-UMIN000020615
|
| Associated Drug: |
Canagliflozin
|
| Title: |
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Patients of type 2 diabetes mellitus with nonalcoholic fatty liver disease (NAFLD).
|
| Interventions: |
canagliflozin100mg/day
|
| Outcome Measures: |
Hepatic fat fraction (HFF) by hepatic magnetic resonance imaging (MRI) after 6 or 12 months.body weight, HbA1c, glucagon, type IV collagen, hyaluronic acid and NAFLD fibrosis score.
|
| Sponsor/Collaborators: |
Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine.
|
| Gender: |
All
|
| Age: |
20years-old75years-old
|
| Phases: |
Not selected
|
| Enrollment: |
20
|
| Study Type: |
Interventional
|
| Study Designs: |
Single arm Non-randomized
|
| Start Date: |
01/02/2016
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
2 April 2019
|
| Locations: |
Japan
|
| URL: |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023342
|
